NEW YORK (GenomeWeb News) – Kreatech Diagnostics and Oridis Biomarkers today said that they will co-develop and commercialize DNA-FISH assays for oncology applications.
The firms intend to develop the assays as companion diagnostics for pharmaceutical firms conducting pre-clinical and clinical development of new compounds. Amsterdam, The Netherlands--based Kreatech said that it expects to begin commercializing assays in the second half of this year.
According to the partners, the first assay developed under the collaboration will detect amplification of the fibroblast growth factor receptor 1 gene, which has been implicated in several cancer types including lung, breast, prostate, and bladder cancers.
"By using Oridis' expertise in clinical testing and its access to extensive bio banks we have the opportunity to bring our customized FISH4U program to the next level," Kreatech CEO Kees Moonen said in a statement. "With this collaboration we are able to contribute to successful clinical development of novel pharmaceutical compounds as well as to the development of companion diagnostics."
Terms of the collaboration agreement were not disclosed.
Oridis is a contract research organization based in Graz, Austria. It specializes in cancer research and offers biomarker evaluation, patient stratification, antibody profiling, and diagnostic assay development services.